(Rac)-Finerenone Manufacturers: A Complete 2026 Guide

Finerenone has become one of the more closely watched molecules in cardiovascular and renal drug development, and that attention has pushed upstream demand toward its chiral and racemic precursors. Buyers who search for recommended (Rac)-Finerenone manufacturers are usually not looking for a catalog listing. They are looking for a supplier whose process route, impurity control, documentation, and scale can survive regulatory scrutiny and commercial pressure at the same time. This guide explains what actually distinguishes a reliable supplier in this niche, and how Shandong Tianming Pharmaceutical Group positions itself within it.

What (Rac)-Finerenone Is and Why Supplier Choice Matters

(Rac)-Finerenone is the racemic form of Finerenone, a nonsteroidal mineralocorticoid receptor antagonist. Because the therapeutic activity resides in a defined stereochemistry, the racemic material functions as both a synthetic reference point and a control benchmark: it helps define how cleanly a route resolves the desired enantiomer and how well a specification distinguishes active material from its mirror-image counterpart.

That is why procurement decisions here are rarely driven by price alone. Three attributes dominate:

• Chiral purity control. A supplier must demonstrate consistent enantiomer separation, not a single good batch.
• Impurity profiling. Buyers need to know not only what impurities exist, but at what levels, with supporting methodology.
• Route maturity. A route that works in a gram-scale flask often fails at pilot and commercial scale, and the failure appears late.

Finerenone appears in the Shandong Tianming Pharmaceutical Group portfolio under its anti-tumor and specialty product range, listed as Finerenone, CAS 1050477310, alongside precursor building blocks that support route development.

What Separates a Recommended Manufacturer From an Available One

Quality Specifications That Can Be Audited

Registration-grade supply depends on specifications that are stated, reproducible, and documented. Across its flagship chiral intermediate families, Shandong Tianming Pharmaceutical Group holds individual impurities below 0.1% and chiral purity above 99.5%, with monitoring extended to residual solvents, particle size, and crystal form where relevant. For its Orforglipron intermediate series, published control points include individual impurity below 0.1%, total impurities below 0.5%, enantiomer below 0.1%, and content above 98.0%.

The same control philosophy — full quality oversight from raw material receipt through in-process control to finished product release — is what buyers should expect when qualifying a (Rac)-Finerenone manufacturer.

Capacity and Stage Coverage

Many suppliers can deliver a gram. Far fewer can deliver the same molecule from laboratory small-batch through pilot scale-up to commercial mass production without changing the route. Shandong Tianming Pharmaceutical Group operates three production bases with over 160 reactor vessels and annual production capacity in the hundreds of tons, supported by safety stock planning and elastic capacity reserves. Supply is structured from gram-level to ton-level, so an analytical reference standard and a commercial batch can come from the same technical lineage.

Documentation for Global Filings

Technical documentation is frequently the real bottleneck. Complete COA, MOA methodology, impurity profile studies, and stability data are required to support DMF and CEP filings. The group provides this documentation set and offers multiple key impurity reference standards for quality analysis and method development, which shortens the analytical work a customer must repeat internally.

Shandong Tianming Pharmaceutical Group at a Glance

Founded in 2020 as a group, with predecessor Shandong Sihuan Pharmaceutical Co., Ltd. established in 2010, the company is headquartered in Jinan, Shandong Province. It employs over 400 people and holds National High-Tech Enterprise status, alongside provincial recognitions including Shandong Province Gazelle Enterprise, Shandong Province Specialized and Innovative SME, and Guangxi Gazelle Enterprise designations, and ISO9001 quality management certification.

Its footprint includes two R&D centers — in Jinan and Nanjing — with more than 6,000 square meters of laboratory space, an R&D team of over 100 personnel, and over RMB 40 million in analytical equipment spanning HPLC, gas chromatography, mass spectrometry, LC-MS, and chiral analysis instruments. The group holds 20 invention patents and 40 utility model patents, and invests above 10% of annual revenue in R&D, with a further 1% allocated to management system iteration. More than 2,000 cooperative customers are served across domestic pharmaceutical clusters and international markets in 30+ countries.

The Finerenone Product Line Within the Portfolio

The Finerenone entry is supported by structurally related building blocks already in commercial supply:

• Finerenone | CAS: 1050477310
• 4-Amino-5-methyl-2-hydroxypyridine | CAS: 95306642
• Ethyl 2-cyanoacetoacetate | CAS: 65193875
• 4-Cyano-2-methoxybenzaldehyde | CAS: 21962458

Procuring these from a single source reduces multi-supplier coordination, which is a recurring cost driver when routes require several distinct building blocks. For customers needing material that is not catalog-standard, the group offers CMO/CDMO custom development and production, custom synthesis, process optimization, impurity customization, and new compound development — capabilities that matter when a (Rac)-Finerenone requirement is specification-driven rather than off-the-shelf.

Service Model and Delivery Reliability

Supplier qualification does not end at the specification sheet. Practical service terms include:

• In-stock orders delivered within 7–15 working days
• 1-on-1 account manager plus technical engineer support
• Routine technical issues addressed with reference solutions within 2 hours; complex issues resolved with a written report within 24 hours
• Cold chain available for temperature-sensitive products; nitrogen-filled vacuum packaging for oxidation-sensitive materials
• Transport insurance on every order, with compensation and free replacement for transport-related quality damage

For bulk and framework customers, periodic follow-up visits and on-site technical support are available. CRM, ERP, and BPM digital systems coordinate order management, inventory, production scheduling, and customer service.

A Practical Supplier Checklist

When evaluating (Rac)-Finerenone manufacturers, ask for the following:

1. Batch-level analytical data, not a single certificate — chromatograms for chiral and achiral purity.
2. Route disclosure at the level your filing requires, including whether the route is suited to industrial scale-up.
3. Scale evidence: reactor capacity, tonnage capability, and whether the same route runs at pilot and commercial scale.
4. Documentation set: COA, impurity profile studies, stability data, and methodology suitable for DMF or CEP support.
5. Response commitments in writing, particularly technical escalation timelines.

Conclusion

Finerenone programs reward suppliers who can hold chiral specifications across scales. Shandong Tianming Pharmaceutical Group combines an integrated R&D-production model, over 160 reactor vessels across three bases, a registration-grade quality system, and a service structure built for both gram-level reference standards and commercial tonnage — a combination that makes it a credible option for buyers seeking dependable (Rac)-Finerenone and Finerenone-related intermediates.